ArticleBMC pharmacology & toxicology2026
Association of ACEIs/ARBs treatment with clinical outcomes in acute kidney injury: a multicenter retrospective cohort analysis.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundACEIs/ARBs (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) constituted the cornerstone of therapy for various cardiovascular and renal disorders. The appropriate management of ACEIs/ARBs in the acute kidney injury (AKI) remained controversial.
methodsIn this multicenter study involving 1,285 AKI patients, we investigated the associations of ACEIs/ARBs discontinuation (n = 436), persistence (n = 657), and initiation (n = 192) with 14-day AKI progression and mortality. Multivariate logistic regression analysis and subgroup analyses were conducted to evaluate the associations between ACEI/ARB utilization patterns and clinical outcomes.
resultsThe persistence usage of ACEIs/ARBs was independently associated with lower odds of 14-day AKI progression compared to discontinuation (adjusted OR 0.44, 95% CI 0.29-0.67, P < 0.001) Regarding 14-day mortality, the persistence usage of ACEIs/ARBs exhibited an inverse correlation in the unadjusted model (OR 0.30, 95% CI 0.13-0.71, P = 0.006), but the association was attenuated after full adjustment model (OR 0.39, 95% CI 0.13-1.20, P = 0.101). No statistically significant differences in the risk of 14-day AKI progression or mortality were observed between the initiation and discontinuation cohorts across all models.
conclusionsIn this retrospective cohort, the persistence of ACEI/ARB at the onset of AKI was associated with lower odds of 14-day progression, but not mortality. For the 14-day mortality, due to limited events, wide-ranging confidence intervals, and post-adjustment attenuation, these statistical instabilities need highly conservative interpretation and prospective validation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.